OD-002 / Odyssey Therap - LARVOL DELTA

SLC15A4 Inhibitor, OD-002, Selectively Blocks Pathogenic B Cell Responses (ACR Convergence 2026) - "Current approaches to deplete B cells share a common liability: they ablate the protective and regulatory repertoire alongside the pathogenic one, predisposing patients to hypogammaglobulinemia, impaired vaccine responses, and infection. Selective silencing of the pathogenic B cell/pDC program by targeting SLC15A4 with molecules like OD-002 hold the potential for robust efficacy but with increased safety and convenience for patients."

Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • CD40LG • IRF5

Odyssey Therapeutics Discloses…Details Pipeline Timelines and Cash Runway in New SEC Filing (Minichart) - "For OD-002, an oral SLC15A4 inhibitor targeting B cell-mediated diseases, the company announced it is on track to file a Clinical Trial Application (CTA) in H2 2026 and initiate a Phase 1/2 trial in H1 2027. The trial will initially evaluate the drug in cutaneous lupus erythematosus (CLE). Efficacy readouts from the Phase 2a portion are expected in H2 2028....The company’s preclinical TNFR2 agonist program, OD-003, is currently in IND-enabling studies, targeting indications like atopic dermatitis and alopecia areata."

New P1/2 trial • P2a data • Preclinical • Alopecia • Atopic Dermatitis • Cutaneous Lupus Erythematosus • Immunology